Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DSM invests in IntegraGen

This article was originally published in The Tan Sheet

Executive Summary

The Netherlands-based firm has invested $2.6 mil. (€1 = $1.28) in IntegraGen, a French biotechnology company specializing in the development and delivery of genetic tests for rapid diagnosis and better treatment of complex diseases, DSM announces Nov. 7. "IntraGen's proprietary GenomeHIP technology platform identifies disease genes by allowing the rapid comparison of genomes of family members affected with the same disease," the release states. IntegraGen also "recognizes the potential of its know-how in personalized nutrition," which has led to a collaboration program in the area of weight management, the release says. Recently, DSM collaborated with the European Genetic Alliances Network and the International Genetic Alliance to promote health management and "the contribution of functional foods ingredients" to patient and consumer organizations (1"The Tan Sheet," Oct. 30, 2006, In Brief)...

You may also be interested in...



DSM preventive health collaboration

DSM Food Specialties is strengthening its work with patient organizations European Genetic Alliances Network (EGAN) and the International Genetic Alliance (IGA) to promote health management and "the contribution of functional food ingredients" to patient and consumer organizations, policy makers and the general public, according to a release from The Delft, The Netherlands-based ingredient firm. "This collaboration will help us gain better insight into patient needs in order to develop products that meet these needs," said Philip Rijken, the head of nutritional science. "Together we aim to further promote evidence-based development of functional food ingredients and nutritional products which are effective in optimizing and maintaining health in general or in reducing chronic/genetic disease risk"...

Teva Takes On Amneal With Second US NuvaRing Rival

Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.

Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel